Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Probiotix Health's Debt-to-Equity or its related term are showing as below:
During the past 7 years, the highest Debt-to-Equity Ratio of Probiotix Health was -2.17. The lowest was -2.24. And the median was -2.20.
FRA:X90's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Probiotix Health Debt-to-Equity Related Terms
Probiotix Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Probiotix Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:X90 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Probiotix Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Probiotix Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (FRA:X90) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Probiotix Health and its competitors. According to the industry distribution chart, Probiotix Health ranks #999999 out of 955 companies in the Biotechnology industry.
Is Probiotix Health's Debt-to-Equity too high?
Probiotix Health's current Debt-to-Equity is 0.00. Based on the distribution chart, Probiotix Health ranks #999999 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Probiotix Health has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #999999 out of 955 companies for Debt-to-Equity. This places Probiotix Health in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Probiotix Health and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current Debt-to-Equity of 0.00. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 11.3% above its estimated fair value. The current Debt-to-Equity is 0.00. Probiotix Health's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Probiotix Health (FRA:X90) Overvalued in 2026?
Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued.
The current stock price of €0.09 is trading 11.3% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:X90:
Debt-to-Equity: 0.00
GF Value™: €0.08 vs. price of €0.09 (11.3% above fair value)
No single metric tells the full story. See the FRA:X90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
27GF Score
Get the complete analysis for FRA:X90
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:X90 has been successfully added to your 
